Updates

** Shares of Outlook Therapeutics OTLK.O rise 11.6% to $1.29

** Drugmaker says the U.S. FDA has accepted for review its resubmitted marketing application for ONS-5010, branded as Lytenava, after declining approval in December

** OTLK's Lytenava targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina

** Resubmission has been classified as a Class 1 review, with a target action date of July 29, co says

** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab

** Including session's moves, stock down 24% this year